Fig. 1From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisPartitioned survival model simulating outcomes for the CheckMate 743 trial. NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, PFD Progression-free disease, PD Progressed diseaseBack to article page